Synergistic effects of acyclovir and 3, 19- isopropylideneandrographolide on herpes simplex virus wild types and drug-resistant strains

Table 2 Synergistic effects of ACV and IPAD on HSV infection

Compounds combination ratio	Compound concentration (μM)		% Inhibition of IPAD + ACV	Experimental CI	Description
Compounds combination ratio	IPAD	ACV	% Inhibition of IPAD + ACV	Experimental CI	Description
HSV-2
	20.50	-	100
	-	20.20	100
IC ₁₀₀ xIC ₁₀₀	20.50	20.20	100
IC ₅₀ xIC ₅₀	18.01	0.80	100
IC ₁₀ xIC ₁₀	15.00	0.04	100	<1	synergism
	18.01	0.0008	50
	0.004	0.80	50
HSV-1 KOS
	20.50	-	100
	-	20.20	100
IC ₁₀₀ xIC ₁₀₀	20.50	20.20	100
IC ₅₀ xIC ₅₀	16.96	0.49	100
IC ₁₀ xIC ₁₀	13.87	0.02	100	<1	synergism
	16.96	0.008	50
	0.009	0.49	50
HSV-1 ACGr4
	20.50	-	100
	-	2,220.00	100
IC ₁₀₀ xIC ₁₀₀	20.50	2,220.00	100
IC ₅₀ xIC ₅₀	17.89	575.91	100
IC ₁₀ xIC ₁₀	14.96	25.36	88.5	<1	synergism
	17.89	58.16	50
	0.89	575.91	50
HSV-1 dlsptk
	20.50	-	100
	-	2,220.00	100
IC ₁₀₀ xIC ₁₀₀	20.50	2,220.00	100
IC ₅₀ xIC ₅₀	16.86	450.25	98.55
IC ₁₀ xIC ₁₀	15.00	23.12	88.41	< 1	synergism
	16.86	4.51	50
	0.85	450.25	50
HSV-1 dxpIII
	20.50	-	100
	-	2,220.00	100
IC ₁₀₀ xIC ₁₀₀	20.50	2,220.00	100
IC ₅₀ xIC ₅₀	17.12	161.45	100
IC ₁₀ xIC ₁₀	14.90	18.70	100	< 1	synergism
	17.12	0.16	50
	0.009	161.45	50

ISSN: 2662-7671